Skip to main content

Regulatory and Washington

  • NCPA emphasizes Dispose My Meds program during Patient Safety Awareness Week

    ALEXANDRIA, Va. — In line with Patient Safety Awareness Week, which began Sunday, the National Community Pharmacists Association is encouraging patients to properly dispose of their expired or unused medications safely and effectively.

  • Merck seeks FDA approval for Saflutan

    WHITEHOUSE STATION, N.J. — The Food and Drug Administration has accepted an approval application from Merck for a drug to treat eye diseases, Merck said Wednesday.

    Merck is seeking approval for Saflutan (tafluprost) ophthalmic solution, an investigational drug for relieving eye pressure in patients with glaucoma and ocular hypertension.

  • Tris seeks FDA OK for allergy treatment for kids

    MONMOUTH JUNCTION, N.J. — The Food and Drug Administration has accepted a regulatory approval application from Tris Pharma for a drug to treat allergies in children ages 2 years and older, Tris said Wednesday.

    Tris said that if approved, its carbinoxamine extended-release oral suspension would provide an alternative to currently available immediate-release formulations.

  • Third annual NACDS RxImpact Day in full swing

    ALEXANDRIA, Va. — Capitol Hill will turn into a sea of white lab coats Wednesday and Thursday as more than 350 pharmacy advocates from almost 40 states visit Washington for the third annual National Association of Chain Drug Stores RxImpact Day, NACDS said Wednesday.

    The event will include pharmacy and retail executives, division and store managers, pharmacists, pharmacy school deans and students advocating on behalf of pharmacy to members of Congress.

  • APhA begins search for new CFO

    WASHINGTON — The American Pharmacists Association is looking for a new CFO to replace Roger Browning, who will retire, the group said Tuesday.

    Browning has worked in senior financial executive positions for the APhA since 1995, serving as SVP finance and CFO since 2007. Before working for the APhA, he was VP finance at the International Franchise Association.

  • Salix issued CRL for Xifaxan

    RALEIGH, N.C. — The Food and Drug Administration declined to approve a drug made by Salix Pharmaceuticals for irritable bowel syndrome, Salix said Tuesday.

    The FDA issued a complete response letter to Salix for Xifaxan (rifaximin), a treatment for nonconstipation IBS and IBS-related bloating. Salix said it had anticipated that it would receive the letter based on an understanding that the agency needed more information related to retreatment.

  • New diabetes drug accepted for review by FDA

    PRINCETON, N.J. — The Food and Drug Administration has accepted a regulatory approval application for a Type 2 diabetes drug from Bristol-Myers Squibb and AstraZeneca, the two drug makers said Tuesday.

    The FDA accepted the application for dapagliflozin, an investigational drug for adults with the disease. The Centers for Disease Control and Prevention estimated that 1-in-11 U.S. adults has diabetes, with 90% to 95% of them having Type 2 diabetes.

    The agency expects to take action on the application in late October.

  • NACDS to host press conference in support of MTM bill

    ALEXANDRIA, Va. — In line with NACDS RxImpact Day on Capitol Hill this week, the National Association of Chain Drug Stores will hold a press conference in support of S. 274, The Medication Therapy Management Empowerment Act of 2011.

    The legislation, which was introduced by Sen. Kay Hagan, D-N.C., and cosponsored by Sens. Al Franken, D-Minn.; Sherrod Brown, D-Ohio; Tim Johnson, D-S.D.; and Ron Wyden, D-Ore., will be discussed Thursday at the Reserve Officers Association.

X
This ad will auto-close in 10 seconds